4.6 Review

TORC2 Structure and Function

Journal

TRENDS IN BIOCHEMICAL SCIENCES
Volume 41, Issue 6, Pages 532-545

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibs.2016.04.001

Keywords

-

Funding

  1. Canton of Geneva
  2. Swiss National Science Foundation
  3. European Research Council Consolidator Grant Programme

Ask authors/readers for more resources

The target of rapamycin (TOR) kinase functions in two multiprotein complexes, TORC1 and TORC2. Although both complexes are evolutionarily conserved, only TORC1 is acutely inhibited by rapamycin. Consequently, only TORC1 signaling is relatively well understood; and, at present, only mammalian TORC1 is a validated drug target, pursued in immunosuppression and oncology. However, the knowledge void surrounding TORC2 is dissipating. Acute inhibition of TORC2 with small molecules is now possible and structural studies of both TORC1 and TORC2 have recently been reported. Here we review these recent advances as well as observations made from tissue-specific mTORC2 knockout mice. Together these studies help define TORC2 structure function relationships and suggest that mammalian TORC2 may one day also become a bona fide clinical target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available